SDC1 and Miyoshi myopathy: ARQ197 (tivantinib), a small molecule, not ATP competitive c-MET inhibitor, also reduced proliferation of MM cell lines and patient-derived CD138+ plasma cells, downregulating c-MET signaling and inhibiting MAPK and PI3K pathways.